Silvia Crescioli is a Business Intelligence Creator at The Antibody Society, where she works on business intelligence and educational research projects. Since 2021, she has been contributing to the "Antibodies to Watch" editorials in mAbs, reviewing antibody therapeutics recently approved or in regulatory review, and forecasting marketing application submissions for the following year.

In 2014, Dr. Silvia Crescioli obtained her PhD in Biomedical Sciences (specialization in Experimental Oncology) from the University of Florence. She then spent eight years as a postdoctoral researcher at King’s College London in the Cancer Antibody Discovery & Immunotherapy group led by Prof. Karagiannis, where she is now a Visiting Research Fellow.

Her research interests focus on the development of antibody therapeutics for both oncology and non-oncology indications, as well as various areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering, and glycoengineering.

Dr. Silvia Crescioli